Picture a doctor injecting a clear liquid into your bladder, aiming a handheld ultrasound probe at the right spot, and watching a small gel form on the screen exactly where it’s needed. That gel holds a cancer drug and releases it slowly, right at the tumor, instead of flooding your whole bloodstream.
It sounds like a pitch deck for a sci-fi startup. But a version of it has already happened, in mice and rabbits, and the results were published in one of the world’s top scientific journals. We’re not close to having this at your local clinic. Still, the idea that medicine could be manufactured inside the patient, rather than in a factory and delivered by pill or needle, has moved from daydream to working prototype.
So how does it work, what could it actually treat, and what has to go right before anyone sees it in a hospital? Let’s take it in order.
A quick note: this article is for general information and isn’t medical advice. Nothing described here is currently available as a treatment for people.
First, what does “printed inside your body” actually mean?
The phrase covers a few different ideas, and it helps to separate them.
Printing on the body. This is the most developed version. Researchers have built handheld and robotic bioprinters that deposit materials, sometimes including living cells, directly onto a wound. It’s called in situ bioprinting, meaning “in place.” Instead of growing a skin patch in a lab and transplanting it later, the printer lays down the material right on the injury.
Printing deep in the body. This is the newer, wilder idea. Here nothing is placed by hand. A liquid is injected, and an outside trigger, such as focused sound waves, solidifies it at a precise spot inside tissue, no incision required.
What gets printed. It might be a gel that carries a drug, a scaffold that helps tissue regrow, or a material that conducts electricity. Cells could in principle be included too. So “medicine” here isn’t just a pill made in a new way. It can mean a structure that delivers treatment or supports healing.
Hold on to that distinction, because headlines tend to blur it. Printing a working replacement organ inside someone is not what’s on the table. Printing a small, useful structure in the right place is.
The breakthrough: printing with sound
The most striking recent result comes from a team at Caltech led by Wei Gao, a professor of medical engineering, and Elham Davoodi, who completed the work as a postdoctoral scholar at Caltech and is now at the University of Utah. They published their method in Science in 2025 under the title “Imaging-guided deep tissue in vivo sound printing.” A summary of the work is on ScienceDaily, and the paper carries the DOI 10.1126/science.adt0293.
They call the technique deep tissue in vivo sound printing, or DISP. Here’s the logic, in plain terms.
The ink
The team starts with a specially designed liquid, a bioink, that can be injected into the body. It contains several ingredients:
- Monomers, the small building blocks that will link into a polymer gel
- Temperature-sensitive liposomes, tiny fat-based capsules that hold the chemical “glue,” known as crosslinking agents
- Gas vesicles, small bacterial structures that show up on ultrasound and act as an imaging marker
- Cargo, which can be a drug, and in other versions, cells or conductive materials
The trigger
Ultrasound is already a familiar medical tool. It’s used in pregnancy scans, and it passes through the body safely and reaches deep. The Caltech team focuses a beam of it on a chosen spot, which warms that tiny area by only a few degrees. According to a ScienceAlert write-up and the Caltech team’s own description, that modest heat makes the liposomes leak their crosslinking agent. The agent then ties the monomers together into a solid hydrogel, but only where the beam was aimed.
Because the gas vesicles change how the material looks on ultrasound as it solidifies, the team can watch the printing happen in real time. That feedback loop is a big deal. It’s the difference between hoping something formed in the right place and seeing that it did.
Why sound instead of light?
Earlier in vivo printing experiments used infrared light. Light is easy to control but doesn’t travel far through flesh, so those methods only worked near the surface. As Gao put it, in comments reported by ScienceAlert, the older approach only reaches right below the skin, while the ultrasound approach reaches deep tissue and can print a variety of materials while keeping biocompatibility.
What they actually showed
The proof-of-concept tests were in animals. According to coverage from The American Ceramic Society, the technique worked in a mouse bladder and in the leg muscles of rabbits. In the bladder work, the printed gel was used for drug delivery aimed at tumor treatment. The team also printed shapes like stars and teardrops in test setups to show how precisely the beam could sculpt the gel.
That’s an exciting result. It’s also a result in mice and rabbits, and I want to be clear about that. Nothing here has been shown to work or be safe in people.
The older, more established cousin: in situ bioprinting
While sound printing grabs headlines, a quieter branch of the field has been moving toward real-world use for longer.
In situ bioprinting generally means putting a bioink directly onto or into a damaged area. Reviews describe two main styles: handheld printers that a clinician holds and moves over a wound, and robotic arms mounted at the bedside that follow a scan of the injury. A 2022 review in Bioengineering & Translational Medicine, available on PubMed Central, discusses how portable handheld bioprinters have been investigated for skin, cartilage, bone, dental, and muscle regeneration.
Burns and large skin wounds are the natural first target. Skin is flat-ish, accessible, and desperately needed after severe injury. A 2025 review in Regenerative Engineering and Translational Medicine, which you can read on Springer, notes that handheld bioprinting is particularly valuable for patients with restricted mobility, such as those with severe burns, since the device can come to the patient rather than the other way around. Researchers in China have even built a smartphone-controlled handheld bioprinter and tested it on skin wounds, as reported by the Shenzhen Institutes of Advanced Technology, with the stated aim of use in settings like battlefields or remote areas.
The honest caveat is that most of this is still preclinical, meaning lab and animal work. A recent review of handheld skin bioprinters, on PubMed Central, frames its goal as assessing how far the technology has come in clinical translation and what’s still missing, which tells you the gap between demo and standard care remains real.
What could actually be printed?
Let’s talk about the practical possibilities, ranked roughly from nearest to furthest.
Drug depots. A gel that sits at a target site and releases medicine over days or weeks is the most plausible near-term use. Think of cancer drugs delivered right at a tumor, or anti-inflammatory medicine placed in a painful joint. The potential upside is higher local dose with fewer side effects elsewhere in the body.
Wound dressings and sealants. Printing a protective, healing-friendly layer directly onto a burn or ulcer is already being explored in animals and early studies.
Scaffolds for tissue repair. A printed framework can give your own cells something to grow on. The Caltech team suggested its approach may eventually support tissue replacement, based on the rabbit muscle results, though that is a long way off.
Bioelectronic materials. Because the ink can include conductive components, researchers have floated printing electrically active hydrogels that could interface with nerves or muscle. That’s early-stage, even by this field’s standards.
Cell-laden structures. Adding living cells to the ink opens the door to regenerative medicine, such as delivering stem cells to a precise location. It also raises the hardest safety and regulatory questions, so expect this one to move slowest.
Notice what’s missing from the list: whole organs. Printing a functional kidney or heart is a separate, much harder problem, and it’s not what in vivo printing is about right now.
The hurdles nobody should gloss over
If you read only the press releases, you’d think this is a year or two from your doctor’s office. It isn’t. A few obstacles are serious.
Safety and biocompatibility
Anything injected and solidified inside you has to be non-toxic, not trigger a harmful immune response, and either stay put safely or break down predictably. Ingredients that look fine in a rabbit may behave differently in a person. Even the heating, though small, needs careful study across different tissues, since blood flow carries heat away at different rates in different places.
Control and dosing
A printed gel releasing a drug is only helpful if it releases the right amount at the right pace. Matching that to individual patients, whose bodies and diseases vary, is a design challenge. So is what happens if the gel forms in the wrong spot or the dose goes wrong, and whether you can remove or reverse it.
Sterility and manufacturing
Reviews of in situ bioprinting keep returning to the same point: biosafety, aseptic handling, and bioink formulations all need improvement before wide clinical use. A bioink is not a pill. It may contain delicate components that must be made consistently, stored properly, and kept sterile.
Regulation
A product that combines a material, a drug, possibly cells, and a device that triggers it doesn’t fit neatly into one regulatory box. Regulators will want evidence on each piece and on how they work together. That process takes years even when the science is clean, and it should. I won’t pretend to know exactly how agencies will classify these systems; the point is that the pathway is complicated and slow.
Human evidence
This is the big one. Moving from animal studies to human trials requires proving safety first, usually starting with small studies. As far as the published reports I reviewed show, the ultrasound-printing work remains at the animal stage. If you read a claim that “printing medicine inside the body” is available to patients, treat it with serious skepticism.
Who could benefit, and who might be left out
If this technology matures, the early winners are fairly easy to guess: people with hard-to-treat tumors, severe burns, chronic wounds that won’t heal, and injuries where precise local treatment beats a system-wide drug.
There’s also a fairness question worth raising. Advanced, personalized treatments tend to start expensive and reach wealthier patients first. Handheld and portable devices could help here, since researchers pitch them as lower-cost and suitable for remote or resource-limited settings, but that’s a promise, not a guarantee. Whether the technology narrows or widens healthcare gaps will depend on pricing, regulation, and who decides to build for whom.
And a word of caution for anyone tempted by shortcuts. Don’t buy “bioprinting kits” or injectable gels from unverified sellers. None of this is something to experiment with outside a regulated clinical trial.
Frequently asked questions
Is in vivo 3D printing available to patients today?
No. The ultrasound-based method has been demonstrated in animals. Some in situ bioprinting approaches for skin are further along, but they’re still being studied and are not routine care.
Is it safe?
That’s exactly what researchers still need to show. Animal results are a promising first step, but safety in people hasn’t been established.
Will I be able to print my own medicine at home?
No, and that’s not the idea. These systems need imaging guidance, controlled ingredients, and trained clinicians.
How is this different from a normal injection?
A normal injection delivers a drug that spreads through your body. Here, the injected liquid is designed to solidify only where it’s triggered, forming a structure that stays put and can release treatment locally.
When might this reach hospitals?
Nobody can responsibly give a date. Medical technologies commonly take many years to move from first animal results to approved use, and some never make it.
Could future medicines be printed inside your body? It’s a reasonable “maybe,” with the emphasis on the “future.” The Caltech sound-printing work showed that injected materials can be solidified deep in living tissue with focused ultrasound, guided by real-time imaging, without surgery. Meanwhile, handheld and robotic bioprinters keep inching toward use on burns and wounds.
What makes the idea compelling isn’t the novelty. It’s the shift in thinking: instead of making a drug somewhere else and hoping it reaches the right place, you build the treatment where the problem is. Whether that turns into a real clinical tool depends on safety data, careful regulation, and years of patient work that doesn’t make headlines.
For now, it’s worth watching, not waiting on.
